Ahmed Gawish1, Matthias Walke2, Burkard Röllich2, Hans-Joachim Ochel2, Thomas B Brunner2,3. 1. Department of Radiation Oncology, University Hospital Magdeburg, Leipziger Str. 44, 39120, Magdeburg, DE, Germany. ahmed.gawish@med.ovgu.de. 2. Department of Radiation Oncology, University Hospital Magdeburg, Leipziger Str. 44, 39120, Magdeburg, DE, Germany. 3. Department of Radiation Oncology, Medical University of Graz, 8036, Graz, Austria.
Abstract
PURPOSE: Oligometastatic prostate cancer is heavily investigated, and conventionally fractionated elective nodal treatment appears to increase biochemical relapse-free (bRFS) survival. The novelty of this report is to present elective nodal radiotherapy (ENRT) with simultaneous integrated boost with stereotactic (SBRT) or hypofractionated radiotherapy (HoFRT) for tolerance and for bRFS which we compared with SBRT of the involved field (IF) only. MATERIALS AND METHODS: Patients between 2018 and 2021 with and oligometastatic prostate cancer treated with SBRT or hypofractionation were eligible. A radiobiologically calculated simultaneous integrated boost approach enabled to encompass elective nodal radiotherapy (ENRT) with high doses to PSMA-positive nodes. A second group had only involved field (IF) nodal SBRT. RESULTS: A total of 44 patients with 80 lesions of initially intermediate- (52%) or high-risk (48%) D'Amico omPC were treated with SBRT to all visible PSMA-PET/CT lesions and 100% of the treated lesions were locally controlled after a median follow-up was 18 months (range 3-42 months). Most lesions (56/80; 70%) were nodal and the remainder osseous. Median bPFS was 16 months and ADT-free bPFS 18 months. ENRT (31 patients) versus IF (13 patients) prevented regional relapse more successfully. At univariate analysis, both initial PSA and length of the interval between primary diagnosis and biochemical failure were significant for biochemical control. Treatment was well tolerated and only two patients had toxicity ≥ grade 3 (1 GU and 1 GI, each). DISCUSSION/ CONCLUSION: SBRT and hypofractionated radiotherapy at curative doses with ENRT was more effective to delay ADT than IF, controlled all treated lesions and was well tolerated.
PURPOSE: Oligometastatic prostate cancer is heavily investigated, and conventionally fractionated elective nodal treatment appears to increase biochemical relapse-free (bRFS) survival. The novelty of this report is to present elective nodal radiotherapy (ENRT) with simultaneous integrated boost with stereotactic (SBRT) or hypofractionated radiotherapy (HoFRT) for tolerance and for bRFS which we compared with SBRT of the involved field (IF) only. MATERIALS AND METHODS: Patients between 2018 and 2021 with and oligometastatic prostate cancer treated with SBRT or hypofractionation were eligible. A radiobiologically calculated simultaneous integrated boost approach enabled to encompass elective nodal radiotherapy (ENRT) with high doses to PSMA-positive nodes. A second group had only involved field (IF) nodal SBRT. RESULTS: A total of 44 patients with 80 lesions of initially intermediate- (52%) or high-risk (48%) D'Amico omPC were treated with SBRT to all visible PSMA-PET/CT lesions and 100% of the treated lesions were locally controlled after a median follow-up was 18 months (range 3-42 months). Most lesions (56/80; 70%) were nodal and the remainder osseous. Median bPFS was 16 months and ADT-free bPFS 18 months. ENRT (31 patients) versus IF (13 patients) prevented regional relapse more successfully. At univariate analysis, both initial PSA and length of the interval between primary diagnosis and biochemical failure were significant for biochemical control. Treatment was well tolerated and only two patients had toxicity ≥ grade 3 (1 GU and 1 GI, each). DISCUSSION/ CONCLUSION: SBRT and hypofractionated radiotherapy at curative doses with ENRT was more effective to delay ADT than IF, controlled all treated lesions and was well tolerated.
Authors: Andrei Fodor; Genoveffa Berardi; Claudio Fiorino; Maria Picchio; Elena Busnardo; Margarita Kirienko; Elena Incerti; Italo Dell'Oca; Cesare Cozzarini; Paola Mangili; Marcella Pasetti; Riccardo Calandrino; Luigi Gianolli; Nadia G Di Muzio Journal: BJU Int Date: 2016-05-24 Impact factor: 5.588
Authors: David A Palma; Cornelis J A Haasbeek; George B Rodrigues; Max Dahele; Michael Lock; Brian Yaremko; Robert Olson; Mitchell Liu; Jason Panarotto; Gwendolyn H M J Griffioen; Stewart Gaede; Ben Slotman; Suresh Senan Journal: BMC Cancer Date: 2012-07-23 Impact factor: 4.430
Authors: Gregor Habl; Christoph Straube; Kilian Schiller; Marciana Nona Duma; Markus Oechsner; Kerstin A Kessel; Matthias Eiber; Markus Schwaiger; Hubert Kübler; Jürgen E Gschwend; Stephanie E Combs Journal: BMC Cancer Date: 2017-05-22 Impact factor: 4.430
Authors: Matthias Guckenberger; Wolfgang W Baus; Oliver Blanck; Stephanie E Combs; Jürgen Debus; Rita Engenhart-Cabillic; Tobias Gauer; Anca L Grosu; Daniela Schmitt; Stephanie Tanadini-Lang; Christos Moustakis Journal: Strahlenther Onkol Date: 2020-05 Impact factor: 3.621
Authors: Simon Kirste; Stephanie G C Kroeze; Christoph Henkenberens; Nina-Sophie Schmidt-Hegemann; Marco M E Vogel; Jessica Becker; Constantinos Zamboglou; Irene Burger; Thorsten Derlin; Peter Bartenstein; Juri Ruf; Christian la Fougère; Matthias Eiber; Hans Christiansen; Stephanie E Combs; Arndt-Christian Müller; Claus Belka; Matthias Guckenberger; Anca-Ligia Grosu Journal: Front Oncol Date: 2021-05-10 Impact factor: 6.244
Authors: Matthew P Deek; Kekoa Taparra; Ryan Phillips; Pedro Isaacsson Velho; Robert W Gao; Curtiland Deville; Daniel Y Song; Stephen Greco; Michael Carducci; Mario Eisenberger; Theodore L DeWeese; Samuel Denmeade; Kenneth Pienta; Channing J Paller; Emmanuel S Antonarakis; Kenneth R Olivier; Sean S Park; Phuoc T Tran; Bradley J Stish Journal: Eur Urol Oncol Date: 2020-06-11